IRIS
TAGLIAMENTO, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.300
AS - Asia 1.071
NA - Nord America 585
SA - Sud America 101
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 7.076
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.094
US - Stati Uniti d'America 567
SG - Singapore 413
CN - Cina 290
VN - Vietnam 196
FR - Francia 64
BR - Brasile 62
HK - Hong Kong 57
FI - Finlandia 50
DE - Germania 29
BD - Bangladesh 16
GB - Regno Unito 15
JP - Giappone 15
AR - Argentina 12
IN - India 11
PH - Filippine 11
MX - Messico 10
ID - Indonesia 7
NL - Olanda 7
IQ - Iraq 6
RU - Federazione Russa 6
UZ - Uzbekistan 6
ZA - Sudafrica 6
CH - Svizzera 5
EC - Ecuador 5
PY - Paraguay 5
TH - Thailandia 5
TR - Turchia 5
CO - Colombia 4
DZ - Algeria 4
TW - Taiwan 4
UY - Uruguay 4
CA - Canada 3
CL - Cile 3
IE - Irlanda 3
IL - Israele 3
KR - Corea 3
MY - Malesia 3
SA - Arabia Saudita 3
SE - Svezia 3
UA - Ucraina 3
VE - Venezuela 3
AL - Albania 2
BE - Belgio 2
EG - Egitto 2
ES - Italia 2
GR - Grecia 2
HR - Croazia 2
JO - Giordania 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PK - Pakistan 2
PL - Polonia 2
RO - Romania 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
KE - Kenya 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
NI - Nicaragua 1
PA - Panama 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 7.076
Salva come PNG Salva come JPEG
Città #
Genoa 2.965
Genova 927
Vado Ligure 630
Rapallo 474
Singapore 198
San Jose 120
Ashburn 113
Council Bluffs 73
Lauterbourg 61
St Louis 60
Ho Chi Minh City 58
Hong Kong 53
Hanoi 46
Helsinki 46
Beijing 42
New York 20
Frankfurt am Main 19
Bordighera 14
Da Nang 14
Milan 13
Los Angeles 12
Tokyo 12
Santa Clara 11
Tianjin 10
City of London 8
São Paulo 7
Mexico City 6
Rome 6
Amsterdam 5
Baghdad 5
Chicago 5
Haiphong 5
Orem 5
Phủ Lý 5
Tashkent 5
Asunción 4
Atlanta 4
Guangzhou 4
Hải Dương 4
Johannesburg 4
Naples 4
Padua 4
Thái Bình 4
Zurich 4
Bologna 3
Brescia 3
Dhaka 3
Dublin 3
Hefei 3
Istanbul 3
Lappeenranta 3
New Delhi 3
Nuremberg 3
Schiffdorf 3
Shanghai 3
Taoyuan District 3
Thái Nguyên 3
Amman 2
Bari 2
Beinasco 2
Biên Hòa 2
Brussels 2
Buffalo 2
Bình Dương 2
Bình Phước 2
Can Tho 2
Caracas 2
Chongqing 2
Dallas 2
Des Moines 2
Fortaleza 2
Guayaquil 2
Gurugram 2
Huế 2
Hưng Yên 2
Jakarta 2
Jersey City 2
Kyiv 2
Lahore 2
Lancaster 2
Lewes 2
Lima 2
London 2
Maldonado 2
Manchester 2
Manila 2
Modena 2
Montevideo 2
Montreal 2
Mumbai 2
Munich 2
Muscat 2
Phoenix 2
Quận Bình Thạnh 2
Rio de Janeiro 2
Salt Lake City 2
Santiago 2
Shenzhen 2
Shijiazhuang 2
Stockholm 2
Totale 6.214
Salva come PNG Salva come JPEG
Nome #
Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis 225
Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: a systematic review and meta-analysis 220
Italian survey on managing immune checkpoint inhibitors in oncology during COVID-19 outbreak 202
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer 175
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis 160
Diagnosis of lung cancer following emergency admission: Examining care pathways, clinical outcomes, and advanced NSCLC treatment in an Italian cancer Center 155
A Circulating Risk Score, Based on Combined Expression of Exo-miR-130a-3p and Fibrinopeptide A, as Predictive Biomarker of Relapse in Resectable Non-Small Cell Lung Cancer Patients 154
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 149
Radiomic detection of EGFR mutations in NSCLC 147
Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives 145
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients 141
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study 140
Novel emerging molecular targets in non-small cell lung cancer 135
Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer 134
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test 130
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 129
Front-line liquid biopsy for early molecular assessment and treatment of hospitalized lung cancer patients 128
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus. 128
Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer 128
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities 122
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate 122
Current state of the art on the diagnosis and the role of target therapy for treatment of ROS1-rearranged non-small cell lung cancer: a narrative review 121
Comparing the gonadotoxicity of multiple breast cancer regimens: Important understanding for managing breast cancer in pre-menopausal women 121
Resistin is associated with overall survival in non-small cell lung cancer patients during nivolumab treatment 118
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives 116
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine 115
Investigational drugs targeting fibroblast growth factor receptor in the treatment of non-small cell lung cancer 112
The role of the immune metabolic prognostic index in patients with non-small cell lung cancer (Nsclc) in radiological progression during treatment with nivolumab 112
Update on the management of breast cancer during pregnancy 110
CD34+DNAM-1brightCXCR4+ haemopoietic precursors circulate after chemotherapy, seed lung tissue and generate functional innate-like T cells and NK cells 110
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 108
Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC 107
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium 105
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds 103
Circulating Osteopontin Predicts Clinical and Radiological Response in First-Line Treatment of Advanced Non-Small Cell Lung Cancer 98
Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors 96
Safety and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer: Focus on challenging populations 95
Call for ensuring cancer care continuity during COVID-19 pandemic 93
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 92
Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient 89
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer 89
Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study 87
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab 82
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 81
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer 81
Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial 81
Performance of the oncomineTM Lung cfDNA assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice 81
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity 66
The evolving scenario of cancer care provision across the COVID-19 pandemic in Europe 62
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta‑analysis” 62
Metabolic tumor volume assessed by 18F FDG - PET CT scan as a predictive biomarker for immune checkpoint blockers in advanced NSCLC and its biological correlates 62
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies 61
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses 61
Biological Rationale for Peripheral Blood Cell–Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer 60
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 60
VISTA: A Promising Target for Cancer Immunotherapy? 58
null 57
Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab 56
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 55
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 51
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations 49
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers 48
Expected medium- And long-term impact of the COVID-19 outbreak in oncology 47
New emerging targets in cancer immunotherapy: The role of VISTA 46
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 46
Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction 42
Oncological care organisation during COVID-19 outbreak 40
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 39
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer 38
Does perioperative immunotherapy reduce the risk of second primary cancers? 36
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors 33
Immune Checkpoint Inhibitors and Targeted Therapies in Early-Stage Non-Small-Cell Lung Cancer: State-of-the-Art and Future Perspectives 33
Heterogeneity of treatment effects in malignant pleural mesothelioma 32
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey 27
Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer 26
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer 26
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer 24
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma 24
Comparison of suboptimal versus adequate ovarian function suppression in premenopausal women with early breast cancer treated with adjuvant endocrine therapy: An exploratory analysis of two prospective studies 21
Upfront osimertinib and as sequential therapy in patients with EGFR-mutant non-small cell lung cancer (NSCLC): benefit across patients groups in a real-world retrospective cohort—the smile study 19
The use of immunotherapy in older patients with advanced non-small cell lung cancer 18
Brief Report: Targeted Therapies and Pancreatitis in Patients With Advanced Nonsmall Cell Lung Cancer 18
Data from Metabolic Tumor Volume Assessed by 18F FDG–PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates 16
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study 16
Neoadjuvant immunotherapy strategies for resectable non-small cell lung cancer (NSCLC): Current evidence among special populations and future perspectives 13
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patients 10
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases 9
The FLARE Score and Circulating Neutrophils in Patients with Cancer and COVID-19 Disease 8
Molecular Tumor Boards: A Consensus Statement From the International Association for the Study of Lung Cancer 8
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer 7
Tackling Non–Small Cell Lung Cancer in Young Adults: From Risk Factors and Genetic Susceptibility to Lung Cancer Profile and Outcomes 7
Time to rethink platinum choices in the era of immunotherapy in lung cancer 6
Totale 7.375
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.442
article - articoli 27.222
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 38
Totale 54.702
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202181 0 0 0 0 0 0 0 0 0 47 12 22
2021/2022394 38 13 9 29 21 25 16 79 32 52 21 59
2022/2023567 43 53 5 48 93 81 7 46 97 12 75 7
2023/2024475 11 33 11 55 27 85 36 36 17 42 39 83
2024/20251.854 78 102 43 115 220 199 202 342 104 91 194 164
2025/20263.460 350 154 580 397 383 224 497 210 300 365 0 0
Totale 7.375